Burrill Starts Cleveland BioLabs (CBLI) at Market Outperform
Tweet Send to a Friend
Get Alerts CBLI Hot Sheet
Price: $1.66 +1.22%
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Rating Summary:
6 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 13
Trade CBLI Now!
Burrill initiates coverage on Cleveland BioLabs (NASDAQ: CBLI) with a Market Outperform. PT $4.00.
The firm comments, "We believe that the company's lead program, Entolimod, has the potential to be used as an antidote for the treatment of Acute Radiation Syndrome (ARS). CBLI aims to secure procurement contracts from the U.S. government. Not entirely reliant on government funding, CBLI has initiated a number of oncology programs, which range from pre-clinical testing to Phase 1/2 development."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.31 yesterday, with a 52 week range of $1.15-$4.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
The firm comments, "We believe that the company's lead program, Entolimod, has the potential to be used as an antidote for the treatment of Acute Radiation Syndrome (ARS). CBLI aims to secure procurement contracts from the U.S. government. Not entirely reliant on government funding, CBLI has initiated a number of oncology programs, which range from pre-clinical testing to Phase 1/2 development."
For an analyst ratings summary and ratings history on Cleveland BioLabs click here. For more ratings news on Cleveland BioLabs click here.
Shares of Cleveland BioLabs closed at $1.31 yesterday, with a 52 week range of $1.15-$4.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Guggenheim Starts Biota Pharmaceuticals (BOTA) at Buy
- Topeka Capital Starts InvenSense (INVN) at Buy
- Topeka Capital Starts Atmel (ATML) at Buy
Create E-mail Alert Related Categories
Hot New Coverage, New Coverage
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
